AN
Time to hopefully help clear up the AN thing, Wish more people would do this rather than make suggestions or inuendos of what they think everyone else is thinking.
A direct quote from an email I sent to AN.
"Pelareorep (formally Reolysin, also known as AN1004), in-licensed from Oncolytics Biotech with exclusive rights in several Asian countries, is currently still developing by us, and we expect to obtain the preliminary safety and efficacy data of the bridging trial later this year or early next year. While we have no intention to change our direction in developing anticancer drugs, our pipeline will only include the ones reflecting our focus on our global strategy"
Now we can draw our own conclusions from this. I already have my thoughts on this but each will have their own interpretation. At least AN got back to me which is better than the onc pr department of late.